The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny-Reference-Cited by-同舟云学术

The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny

Published:2023-07-26 Issue:10 Volume:27 Page:1719-1735
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Nudelman Raphael¹^ORCID,Kocks Grace²^ORCID,Mouton Bruno³^ORCID,Ponting David J.²^ORCID,Schlingemann Joerg³^ORCID,Simon Stephanie³^ORCID,Smith Graham F.⁴^ORCID,Teasdale Andrew⁵^ORCID,Werner Anne-Laure²^ORCID

Affiliation:

1. Teva Pharmaceutical Industries Ltd., 124 Dvorah Haneviah, Tel Aviv 6944020, Israel

2. Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds LS11 5PS, U.K.

3. Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany

4. Data Science and AI, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom

5. Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00100

Reference93 articles.

1. Suspension of ranitidine medicines in the EU. EMA/231394/2020. European Medicines Agency, April 30, 2020. https://www.ema.europa.eu/en/documents/press-release/suspension-ranitidine-medicines-eu_en.pdf (accessed 2023-06-09).

2. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. U.S. Food and Drug Administration, April 1, 2020. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market (accessed 2023-06-09).

3. EMA update on metformin diabetes medicines. EMA/660975/2019. European Medicines Agency, December 6, 2019. https://www.ema.europa.eu/en/documents/press-release/ema-update-metformin-diabetes-medicines_en.pdf (accessed 2023-06-09).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines;Computational Toxicology;2024-03

2. The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD50) for two problematic N-nitrosamines in food: NMAMPA and NMAMBA using toxicology in silico methods;Chemico-Biological Interactions;2024-02

3. Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process;Organic Process Research & Development;2024-01-24

4. An automated carcinogenic potency categorization approach for nitrosamine drug substance-related impurities;Green Chemistry;2024

5. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals;Journal of Pharmaceutical Sciences;2023-12